Kyowa Kirin Resubmits Istradefylline for US Approval for 1st time in 12 Years, Based on Japanese Data

Kyowa Hakko Kirin said on March 1 that it has refiled a new drug application (NDA) with the US FDA for its selective adenosine A2A receptor antagonist istradefylline (development code: KW-6002) for use as adjunctive treatment to levodopa/carbidopa in adult...read more